Pretreatment neutrophil-lymphocyte ratio

Medicine (United States)

Volumn 94, Issue 11, 2015, Pages e639-

  Gao, Fangyuan ^a   Li, Xiaoshu ^a   Geng, Mingfan ^a   Ye, Xieqiong ^a   Liu, Huimin ^a   Liu, Yao ^a   Wan, Gang ^a   Wang, Xianbo ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; GAMMA GLUTAMYLTRANSFERASE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHILD PUGH SCORE; CHINESE; CORRELATIONAL STUDY; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PORTAL VEIN; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR VOLUME; BLOOD; CHINA; EPIDEMIOLOGY; IMMUNOLOGY; LIVER; LIVER TUMOR; LYMPHOCYTE COUNT; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHINA; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84930410128     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000639     Document Type: Article

References (27)

1. Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57:794-802.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-1127.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
4. Camma C, Cabibbo G. Prognostic scores for hepatocellular carcinoma: none is the winner. Liver Int. 2009;29:478-480.
5. Edge SB, Byrd D, Compton CC. AJCC Cancer Staging Manual. From the AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
6. Zhang JF, Shu ZJ, Xie CY, et al. Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort. PloS One. 2014;9:e88182.
7. Bhatti I, Peacock O, Lloyd G, et al. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg. 2010;200:197-203.
8. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
9. Jaiswal M, LaRusso NF, Burgart LJ, et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000;60:184-190.
10. Mano Y, Shirabe K, Yamashita Y, et al. Preoperative neutrophil-tolymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: A retrospective analysis. Ann Surg. 2013;258:301-305.
11. Sharaiha RZ, Halazun KJ, Mirza F, et al. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol. 2011;18:3362-3369.
12. Dan J, Zhang Y, Peng Z, et al. Postoperative neutrophil-tolymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. PloS One. 2013;8:e58184.
13. Kinoshita A, Onoda H, Imai N, et al. Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer. 2012;107:988-993.
14. Sullivan KM, Groeschl RT, Turaga KK, et al. Neutrophil-tolymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma: A Western perspective. J Surg Oncol. 2014;109:95-97.
15. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update. Hepatology. 2011;53:1020-1022.
16. Forner A, Reig ME, de Lope CR, et al. Current strategy for staging and treatment: The BCLC update and future prospects. Semin Liver Dis. 2010;30:61-74.
17. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71-78.
18. Kono H, Fujii H, Ogiku M, et al. Role of IL-17A in neutrophil recruitment and hepatic injury after warm ischemia-reperfusion mice. J Immunol. 2011;187:4818-4825.
19. Poon RT, Fan ST, Lo CM, et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235:373-382.
20. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: A prospective study of 377 patients over 10 years. Ann Surg. 2001;234:63-70.
21. Ziparo V, Balducci G, Lucandri G, et al. Indications and results of resection for hepatocellular carcinoma. Eur J Surg Oncol. 2002;28:723-728.
22. Kusumanto YH, Dam WA, Hospers GA, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6:283-287.
23. McDonald B, Spicer J, Giannais B, et al. Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer. 2009;125:1298-1305.
24. Wu Y, Zhao Q, Peng C, et al. Neutrophils promote motility of cancer cells via a hyaluronan-mediated TLR4/PI3K activation loop. J Pathol. 2011;225:438-447.
25. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565-1570.
26. Muller I, Munder M, Kropf P, et al. Polymorphonuclear neutrophils and T lymphocytes: strange bedfellows or brothers in arms? Trends Immunol. 2009;30:522-530.
27. Rashid F, Waraich N, Bhatti I, et al. A pre-operative elevated neutrophil:lymphocyte ratio does not predict survival from oesophageal cancer resection. World J Surg Oncol. 2010;8:1.